Deep vein thrombosis cost-effectiveness of therapy

Jump to navigation Jump to search

Editor(s)-In-Chief: The APEX Trial Investigators, C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Cafer Zorkun, M.D., Ph.D. [2] Ujjwal Rastogi, MBBS [3]; Kashish Goel, M.D.; Assistant Editor(s)-In-Chief: Justine Cadet

Deep Vein Thrombosis Microchapters

Home

Patient Information

Overview

Classification

Pathophysiology

Causes

Differentiating Deep vein thrombosis from other Diseases

Epidemiology and Demographics

Risk Factors

Triggers

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Approach

Assessment of Clinical Probability and Risk Scores

Assessment of Probability of Subsequent VTE and Risk Scores

History and Symptoms

Physical Examination

Laboratory Findings

Ultrasound

Venography

CT

MRI

Other Imaging Findings

Treatment

Treatment Approach

Medical Therapy

IVC Filter

Invasive Therapy

Surgery

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Special Scenario

Upper extremity DVT

Recurrence

Pregnancy

Trials

Landmark Trials

Case Studies

Case #1

Deep vein thrombosis cost-effectiveness of therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Deep vein thrombosis cost-effectiveness of therapy

CDC on Deep vein thrombosis cost-effectiveness of therapy

Deep vein thrombosis cost-effectiveness of therapy in the news

Blogs on Deep vein thrombosis cost-effectiveness of therapy

Directions to Hospitals Treating Deep vein thrombosis

Risk calculators and risk factors for Deep vein thrombosis cost-effectiveness of therapy

Overview

In United States, deep vein thrombosis DVT and pulmonary embolism PE costs are[1]:

  • Initial hospitalization, average more than $9,800 and $14,000 respectively;
  • Rehospitalization (over half of which occurs within 90 days) costs average more than $11,800 and $14,700, respectively.

Thus, after major orthopedic surgery, the use of effective VTE prevention strategies can reduce this economic burden.

On the basis of Canadian cost-effectiveness guidelines in the early 1990s, there is moderate to strong evidence to adopt enoxaparin prophylaxis against DVT after total hip replacement.[2]

References

  1. Spyropoulos AC, Lin J (2007). "Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations". J Manag Care Pharm. 13 (6): 475–86. PMID 17672809.
  2. O'Brien BJ, Anderson DR, Goeree R (1994). "Cost-effectiveness of enoxaparin versus warfarin prophylaxis against deep-vein thrombosis after total hip replacement". CMAJ. 150 (7): 1083–90. PMC 1486381. PMID 8137188. Unknown parameter |month= ignored (help)

Template:WH Template:WS